Loading
companiesCompany
Actinium Pharmaceuticals
Actinium Pharmaceuticals attaches the alpha-emitting isotope actinium-225 to antibodies to treat acute myeloid leukaemia and, more recently, solid tumours such as prostate and lung cancer. It is a small listed company whose lead programme is approaching new clinical milestones.
Overview
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), headquartered in New York, develops targeted radiotherapies based on actinium-225 antibody radioconjugates and holds proprietary Ac-225 manufacturing technology. The lead programme Actimab-A is a CD33-targeting, mutation-agnostic therapy for relapsed or refractory acute myeloid leukaemia, with patents extending to solid tumours via myeloid-derived suppressor cells; the company expects clinical milestones from the fourth quarter of 2026. ATNM-400 is a first-in-class Ac-225 pan-tumour radiotherapy in preclinical development for metastatic castration-resistant prostate cancer, non-small cell lung cancer and breast cancer, with 2026 SNMMI data in androgen receptor inhibitor-resistant prostate models and KRAS and EGFR mutant lung models. Iomab-ACT is a targeted conditioning programme. In 2026 the company received NYSE American listing standards notices and appointed Steffen Heeger as Chief Medical Officer.
Headquarters
New York, NY, US
Scorecard
All companies#407of 1244 companies, score 8
- phase 3 +3
- modalities +2
- registry trials +3
0 approved, 1 in phase 3, 0 earlier, 0 targets, 3 registry studies. Formula on the scorecards page.
Type
Radiopharmaceuticals · ATNM
Stage
Public
Website
Phase 3Radioimmunotherapy conditioning agent (anti-CD45 antibody labelled with iodine-131)
Iomab-B is Actinium's radioactive antibody that clears the bone marrow before a transplant for older patients with active relapsed acute myeloid leukaemia; the phase 3 SIERRA trial met its primary endpoint but the FDA asked for another study.
Notes
top- Ticker, exchange and HQ confirmed via SEC EDGAR submissions data (CIK 0001388320). Public company; no private rounds listed. Founding year not sourced.
Similar pages
- CompanyConvergent Therapeutics
Shares Radio-antibody & radio-ADC, Targeted alpha therapy, Prostate cancer.
- CompanyVor Biopharma
Shares CD33, Acute myeloid leukaemia.
- TechnologyAstatine-211 alpha therapy
Shares Targeted alpha therapy, Acute myeloid leukaemia, Prostate cancer.
- CompanyOrum Therapeutics
Shares CD33, Acute myeloid leukaemia.
- CompanyAbdera Therapeutics
- TechnologyAuger-electron therapy
- TrialALFA-0701
Shares CD33, Acute myeloid leukaemia.
- BiomarkerCD33 expression (CD33-positive)
Shares CD33, Acute myeloid leukaemia.
cancers
fronts
technologies
targets
drugs
Phase 3Radioimmunotherapy conditioning agent (anti-CD45 antibody labelled with iodine-131)